Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen
Go back to Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 199.71 +3.13 (1.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $196.58 | 52 Week High | $333.65 | |||
| Open | $199.48 | 52 Week Low | $223.02 | |||
| Day High | $200.98 | P/E | 25.57 | |||
| Day Low | $194.74 | EPS | $7.81 | |||
| Volume | 1,675,269 | |||||
| (NASDAQ: IONS) | Delayed: 75.89 +1.77 (2.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $74.12 | 52 Week High | $62.68 | |||
| Open | $74.85 | 52 Week Low | $19.59 | |||
| Day High | $76.56 | P/E | N/A | |||
| Day Low | $74.12 | EPS | $0.00 | |||
| Volume | 1,956,125 | |||||

